Browse the evidence

Obesity interventions generate substantial social value totaling $15 billion in net social value nationally.

Investing in obesity treatment can lead to significant societal benefits and economic value.

Adverse effects of dual agonists are largely gastrointestinal and manageable.

Healthcare providers should inform patients about the manageable gastrointestinal side effects of dual agonists.

A neural network achieved an overall accuracy of 72.5% in predicting 12-month weight loss from baseline characteristics.

Utilizing neural network models may enhance the prediction of weight loss outcomes in clinical settings.

All exercise groups (WB-EMS, Pilates, Yoga) significantly reduced muscle mass during diet-induced weight loss compared to the control group.

Incorporating exercise like WB-EMS, Pilates, or Yoga can help mitigate muscle loss during weight loss diets.

Patients with less-collapsible upper airways and low loop gain at baseline may be more likely to see improvements in their OSA severity after surgery.

Identifying patients with specific baseline characteristics may help tailor treatment approaches for OSA.

36.7% of adults with obesity but without diabetes had a prescription for semaglutide or tirzepatide that lasted less than 32 days.

Practitioners should be aware that a significant portion of patients may not adhere to GLP-1 RA prescriptions.

Persistent prescriptions (coverage for ≥336 days) were observed in 18.6% of participants.

A minority of patients may maintain long-term use of GLP-1 RAs, indicating potential for sustained treatment benefits.

THDBH120 is a novel long-acting dual GIPR/GLP-1R agonist that has superior weight loss and metabolic improvement effects in rodents and mammals.

THDBH120 may be a promising treatment option for obesity and metabolic disorders.

The activation of GLP-1R by semaglutide or THDBH120 improved lipid metabolism.

GLP-1R activation could be targeted for improving lipid metabolism in obese patients.

The activation of GIPR by LAGIPRA or THDBH120 alleviated inflammation.

GIPR activation may be beneficial for reducing inflammation in obesity-related conditions.

Tirzepatide is associated with a lower risk of dementia versus semaglutide (HR 0.69, 95% CI 0.48-0.99, p = 0.04).

Practitioners may consider tirzepatide as a potentially safer option for reducing dementia risk in patients with type 2 diabetes.

Tirzepatide is associated with lower mortality compared to both semaglutide and SGLT2 inhibitors.

Tirzepatide may offer a survival advantage for patients with type 2 diabetes.

GLP-1 receptor agonists (GLP-1 RAs) have demonstrated anti-inflammatory, antioxidative, and immunomodulatory properties.

GLP-1 RAs may be beneficial in managing inflammation and immune responses.

Tirzepatide improves β-cell function in T2D patients by reprogramming stressed β cells and restoring β-cell identity through FOXO1-dependent transcriptional reactivation.

Practitioners may consider tirzepatide as a therapeutic option for improving β-cell function in T2D patients.

The oleogel-in-oleogel system is capable of delivering fewer calories than fats and most oleogels while still providing essential fatty acids.

This could be a viable alternative for those looking to reduce caloric intake from fats.

Die aktuelle private Finanzierung von GLP-1-Rezeptoragonisten schränkt den Zugang für Menschen mit niedrigem sozioökonomischem Status ein.

Praktiker sollten die finanziellen Barrieren für den Zugang zu GLP-1-Rezeptoragonisten berücksichtigen.

Es gibt ethische Bedenken bezüglich der Verschiebung von Priorisierungen hin zu einer pharmakologischen Behandlung.

Praktiker sollten die ethischen Implikationen der Verschiebung hin zu pharmakologischen Behandlungen bedenken.

An exploratory every-8-weeks regimen showed attenuated efficacy compared to once-monthly dosing.

Practitioners should consider monthly dosing as more effective than less frequent regimens.

Patients with obesity face multiple barriers to cardiac rehabilitation participation and adherence.

Addressing these barriers is crucial for improving CR participation rates among obese patients.

The use of dual and triple agonists was associated with a higher risk of any adverse events (RR 1.13; 95% CI: 1.08-1.19).

Clinicians should be aware of the potential for increased adverse events when prescribing incretin polyagonists.

Gut-derived hormones, the central nervous system, and pancreatic function interact to maintain energy homeostasis.

Understanding the interplay of these systems can inform strategies for addressing metabolic disorders.

Perturbation of gut-brain-pancreas communication contributes to metabolic disorders such as obesity and type 2 diabetes.

Recognizing these perturbations can guide therapeutic approaches for metabolic disorders.

Emerging therapeutic approaches aim to engage multiple bioenergetic pathways to restore metabolic equilibrium.

Practitioners should consider multi-target approaches in developing treatments for metabolic dysfunction.

The presence of metabolic abnormalities doubles event rates associated with obesity, with risk increasing with the number of metabolic abnormalities present.

Practitioners should consider the presence of metabolic abnormalities when assessing the risks of obesity in patients.